UK-based contract research organisation (CRO) Chiltern International will provide pharmacovigilance/safety reporting and medical information services in Western Europe to Pinnacle Biologics, a recently formed “full-service pharmaceutical and biotech solutions company”, under a new agreement.

No financial terms were disclosed. Pinnacle, a privately owned US company with executive offices in Bannockburn, Illinois, was set up last year offering a “total solution” to pharmaceutical and biotechnology companies that want either to launch products or to optimise their value late in the life cycle.

The solution includes regulatory, sales, marketing, distribution (including billing and collections), pharmacovigilance, product safety, market research and administrative services.

James Miller, president and chief executive officer of Pinnacle Biologics, said the agreement with Chiltern was “a significant step in the process of offering a full range of services and solutions to the pharmaceutical/biotechnology companies that we currently represent or will partner with in the future”.